Wednesday, June 10, 2026

Patent intelligence · US

US 10034834

Compositions and methods for treating skin conditions

granted A61KA61K2800/21A61K2800/412A61K2800/49
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 12
Applicant portfolio 8,292
Patent details — US 10034834
Jurisdiction
US
Status
granted
Grant date
Jul 31, 2018
Expiration
Jul 26, 2038
Claims
16
CPC classes
A61K, A61K2800/21, A61K2800/412, A61K2800/49
View on Google Patents ↗

Quick answer

US 10034834 (Compositions and methods for treating skin conditions) is held by AQUA REGENERATIVE THERAPIES LLC. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K2800/21, A61K2800/412, A61K2800/49, A61K2800/524, A61K2800/82

More from AQUA REGENERATIVE THERAPIES LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 10034834?

US 10034834 (Compositions and methods for treating skin conditions) is held by AQUA REGENERATIVE THERAPIES LLC. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10034834?

AQUA REGENERATIVE THERAPIES LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 10034834 expire?

Our index shows an expiration date of Jul 26, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.